Molecular and clinical patterns of local progression in the pancreatic remnant following resection of pancreatic intraductal papillary mucinous neoplasm (IPMN)
Review Article

Molecular and clinical patterns of local progression in the pancreatic remnant following resection of pancreatic intraductal papillary mucinous neoplasm (IPMN)

Elisabetta Sereni1, Claudio Luchini2, Roberto Salvia1, Antonio Pea1

1Unit of General and Pancreatic Surgery, 2Department of Pathology, University of Verona Hospital Trust, Verona, Italy

Contributions: (I) Conception and design: E Sereni, A Pea; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Antonio Pea. Unit of General and Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy. Email:

Abstract: Intraductal papillary mucinous neoplasms (IPMN) are pancreatic cystic lesions that can progress to invasive carcinoma. Consensus guidelines indicate surgery for IPMN at high risk of malignant progression, as assessed by specific radiological and clinical criteria, whereas an active radiological surveillance is recommended for IPMN at low risk of malignancy. The management of IPMN is further complicated by the risk of developing a distinct new cyst or a ductal adenocarcinoma in the remnant pancreas, either synchronously or metachronously. Several studies therefore investigated local progression in the remnant pancreas following partial pancreatic resection for IPMN and whether an unstable epithelium at risk for malignant degeneration may exist. Understanding the biological mechanisms behind progression of IPMN will help in identifying patients that would benefit from the resection of the entire pancreas.

Keywords: Local progression; resected intraductal papillary mucinous neoplasm (resected IPMN)

Submitted Mar 21, 2019. Accepted for publication Apr 18, 2019.

doi: 10.21037/cco.2019.04.03


Intraductal papillary mucinous neoplasms (IPMN) are pancreatic cystic lesions, characterized at pathology by dysplastic mucin-producing epithelium growing into the ductal system (1,2) and by neoplastic progression from low- to high-grade of dysplasia and to invasive carcinoma.

They are morphologically classified as main-duct (MD-IPMN), branch-duct IPMN (BD-IPMN) and mixed-type IPMN (MT-IPMN) based on the pancreatic duct involvement. Risk of harboring malignancy strongly correlates with the duct involvement with a high-risk disease [high-grade of dysplasia (HGD) and invasive carcinoma] being present in 61.6% of resected MD-IPMN and in 18.5% of resected BD-IPMN (3).

Based on histology and mucins expression, IPMN can be classified in four epithelial subtypes: gastric, intestinal, pancreatobiliary and oncocytic, each characterized by a different risk of malignant progression. Gastric type IPMN are usually low-grade lesions, whereas intestinal and pancreatobiliary type IPMN tend to be high-grade lesions and are often associated with invasive carcinoma (4,5).

Management of IPMN presents several clinical challenges. Over the years, consensus guidelines have defined the clinical and radiological criteria for the surgical vs. observational management of IPMN. According to the last set of guidelines, surgery is mandatory in case of ‘high risk stigmata’ (i.e., obstructive jaundice, enhancing mural nodules, main pancreatic duct >10 mm), whereas the presence of ‘worrisome features’ (i.e., pancreatitis, cyst >3 cm, thickened/enhancing cyst walls, main duct size 5–9 mm) warrant further specific studies. Considering that IPMN mostly occur in elderly patients and the annual rate of progression to HGD or invasive cancer is relatively low (1.4–6.9%), in absence of signs predictive of malignancy, the management is therefore conservative (6). Moreover the management of IPMN is further complicated other peculiar characteristics of IPMN. The first is represented by the frequent finding of multifocal cystic lesions along the entire pancreas. The second is the increased risk of developing a distinct cyst or ductal adenocarcinoma (PDAC) in the remnant pancreas separate from the index cyst, either synchronously or metachronously. In this review we will focus on neoplastic progression in the remnant pancreas following pancreatic resection for IPMN. Using the term “local progression” we will therefore refer to the development of new lesions of unknown biological relatedness with the index cyst, whereas with the term “recurrence” we will refer to the reappearance of the same pancreatic disease in the remnant pancreas (locally) or with metastases (systemic).

Biological models of local progression

In recent years, progresses have been made in characterizing the genetic alterations underlying IPMN tumorogenesis. Next generation sequencing techniques have been used to demonstrate heterogeneity within the same cyst and to study molecular events underlying progression from low-grade lesions to invasive carcinoma. Comparing genomic alterations of multifocal and metachronous lesions allowed the development of spatial models of local progression across the entire pancreatic gland (Table 1).

Table 1
Table 1 Molecular analyses investigating patterns of local progression following partial pancreatic resection for IPMN
Full table

Pea et al. (9) modelled tumor progression in the remnant pancreas by characterizing genetic alterations of pancreatic neoplasms in patients who underwent surgical resection for IPMN and had subsequent completion pancreatectomy for progressive disease in the remnant. In addition, in order to study the relation between synchronous but anatomically separated lesions, they also included in the study patients who underwent a resection for pancreatic ductal adenocarcinoma (PDAC) and had a concomitant IPMN.

Comparing molecular alterations, they assessed the relatedness of multifocal lesions and proposed 3 principal mechanisms responsible for local progression in the remnant pancreas.

Among patients with negative resection margins, clonally independent primary lesions were observed, some of them presenting HGD or invasive carcinoma. One explanation is that HGD IPMN could be the result of a diffusely unstable ductal epithelium prone to malignant degeneration, according to a widespread “field defect”. This concept is further corroborated by evidences from clinical observations that concomitant PDAC presenting different genetic alterations can develop in different area from the index IPMN in patients undergoing resection and in those under surveillance for benign-appearing cysts (6). In order to investigate an inherited predisposition underlying the development of IPMN, Skaro et al. (11) recently evaluated germline variants from 315 patients with surgically resected IPMN. Among these, 3% presented germline mutations associated with pancreatic cancer and had a higher risk of developing concurrent invasive carcinoma. This is consistent with previous data on patients with familial pancreatic cancer, as more precursor lesions are observed in their pancreas than in patients without a family history (12,13).

Another less likely explanation for independent multifocal lesions is that the progressive lesion is the result of subclones of the original IPMN that were not used for the genetic analysis and seeded through the pancreatic ducts. This theory is in accordance to the already demonstrated polyclonality within the same cystic lesion (14).

When an IPMN was present at the resection margin, different outcomes were observed according to the grade of dysplasia at the margin. In case of HGD, the progressive lesion was genetically concordant, suggesting a direct extension of the IPMN in the remnant pancreas. When the margin lesion had LGD, the primary lesion, the lesion at the margin and the progressive lesion in the remnant were genetically independent. This is in line with data by Matthaei et al. (7) demonstrating that the majority of multifocal IPMN that arise in the branch ducts and harbor LGD in the lining epithelium are clonally independent.

In the study of Pea et al., in one case with negative margins, a metachronous PDAC presented the same genetic alterations of the index IPMN. This is consistent with Tamura et al. (8) that analysed entire pancreatectomy specimens and described clonally related lesions separated by uninvolved pancreatic duct. Taken together, these data suggest that coexisting multisegmental IPMN involving different area of the main pancreatic duct may be generated by mutant clones spreading through the pancreatic ductal system (as recently demonstrated for PanIN lesions) (15).

Using a similar approach, a recent study by Omori et al. (10) analysed for genetic alterations the epithelium of non-invasive IPMN and the adjacent concurrent invasive carcinoma. By genetic mapping different area from the same IPMN they proposed 3 distinct models of neoplastic progression to invasive carcinoma. In the “sequential subtype”, a progression from the coexisting IPMN with LGD to invasive carcinoma is documented with the invasive cancer sharing driver mutations with all concurrent IPMN. In the “branch-off subtype” the IPMN and the adjacent PDAC have identical KRAS but different GNAS mutations suggesting a clonal origin with later divergence. In “de novo subtype” no driver mutations are shared between PDAC and IPMN. When taken together with results from the previous studies, these data suggest complex relationships between multifocal lesions, whereas it still remains unclear the extent to which these issues may challenge IPMN clinical management.

Clinical patterns and predictors of local progression

Resected IPMNs have a good prognosis in terms of survival with a 10% and 27% range of progression rate in literature (16-19), however not all patients that recur will require an additional resection or will develop an invasive carcinoma. While the majority of patients with invasive carcinoma usually experience distant metastatic recurrences, only a minority of studies focused on the clinical patterns of progression following resection for non-invasive IPMN (Table 2). In the attempt of classifying these patterns, Pea et al. (9) described the radiological characteristics of progressive lesions arising in the remnant pancreas after resection of 260 non-invasive IPMN. “BD progression” was defined as a new BD-IPMN, an increase in size of an existing BD-IPMN, or development of a new solid component within an existing BD-IPMN; “MD progression”, as an increasing dilatation of the main duct dilation and, “solid mass progression”, as the development of a solid mass suspicious for PDAC in the remnant pancreas. In the second case, a stable dilatation of the main pancreatic duct over time was not considered progression but likely postoperative stricture of the pancreatic anastomosis, as frequently observed after pancreaticoduodenectomy.

Table 2
Table 2 Studies investigating clinical risk factor for progression after pancreatic resection for IPMN
Full table

Some studies suggested that the risk of local progression is related to the overall grade of dysplasia within the primary IPMN. He et al. (16) analysed 130 resected non-invasive IPMN; among these, 43 (33%) patients present HGD at the final pathology and 22 (17%) developed imaging evidence of a new or progressive IPMN during postoperative follow-up. Among these, 5 patients developed an invasive carcinoma. Similarly, Pea et al. (9) described family history of pancreatic cancer and HGD of the primary tumor as independent risk factors for the development of a high-risk lesion in the remnant pancreas.

Kang et al. (23) analysed 366 patients with IPMN, including 68 with associated invasive carcinoma, and concluded that HGD in the primary tumor was positively correlated with recurrence, whereas a positive resection margin did not. MD IPMN had the higher rate of recurrence and, among histotypes, the intestinal and the pancreatobiliary presented a higher risk of progression in the remnant than the gastric and the oncocytic types (respectively 9.8%, 11.1% vs. 3.4% and 0%).

Several studies analyzed the significance of the margin status during pancreatic resection for IPMN through frozen section or at the definitive histology, not always with concordant results. While both IPMN and PanIN can be found at the resection margin, it is not clear when the pancreatic margin should be considered as “positive” and required additional pancreatic resection.

Frankel et al. (19) investigated 192 resected non-invasive IPMN and observed that any ductal dysplasia (including low grade IPMN and PanIN) at the final surgical was associated with progressive disease (31% with dysplasia at the margin vs. 13% without dysplasia). In this study, recurrence was defined as the development of new cysts in the remnant (31 patients), an IPMN requiring a re-resection (6 patients) and the development of a distinct pancreatic cancer (3 patients).

Fujii et al. (20) analyzed 103 patients resected for non- invasive IPMN. Those harbouring HGD presented an higher rate of local progression (22.7% vs. 4.9%), however with no differences in outcomes according to the resection margin status (respectively 10.7% of progression in patients with LGD at the margin vs. 7.8% in those with negative margins),

Miller et al. (21) analyzed 243 patients who underwent segmental resection for IPMN. Among 191 patients with non-invasive disease, 38 (20%) presented residual IPMN at the initial operation (8 had positive IPMN margins, 23 had further IPMN in the remnant and 7 presented both), one of them developed invasive cancer in the remnant. Among all patients, 31 (20%) developed a new radiographic lesion consistent with IPMN, 3 of them with an associated invasive cancer. Leng et al. (22) shows that the local recurrence rate in non-invasive IPMNs was 3.72% in patients with negative margin versus 9.56% in those with margins positive for any grade of dysplasia.


Over the next years, our understanding on the natural history of IPMN will expand further thanks to the longer follow-up time of patients under surveillance for benign cysts and of patients that underwent resection for IPMN. Local progression in the remnant pancreas following resection for IPMN represents a relevant clinical problem, in particular due to the increased risk of developing a new invasive carcinoma. Different biological mechanisms of neoplastic progression along the gland have been described, however further studies are needed to determine the clinical utility of distinguishing intraparenchymal spread from second primaries.

Overall, the future of IPMN management lies in integrating new molecular approaches with clinical and pathological findings to define specific subgroups that are likely to progress and that would benefit from the resection of the entire pancreas.




Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized entity. Ann Surg 2001;234:313-21. [Crossref] [PubMed]
  2. Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol 2009;100:13-8. [Crossref] [PubMed]
  3. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International Association of Pancreatology, et al: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-97. [Crossref] [PubMed]
  4. Yamada S, Fujii T, Shimoyama Y, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol 2014;21:2444-52. [Crossref] [PubMed]
  5. De Wilde RF, Hruban RH, Maitra A, et al. Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagnostic Histopathol 2012;18:17-30. [Crossref]
  6. Tanaka M, Fernandez-del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738-53. [Crossref] [PubMed]
  7. Matthaei H, Norris AL, Athanasios AC, et al. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 2012;255:326-33. [Crossref] [PubMed]
  8. Tamura K, Ohtsuka K, Ideno T, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: A retrospective review. Ann Surg 2014;259:360-8. [Crossref] [PubMed]
  9. Pea A, Yu J, Rezaee N, et al. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg 2017;266:133-41. [Crossref] [PubMed]
  10. Omori Y, Ono I, Tanino N, et al. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Gastroenterology 2019;156:647-661.e2. [Crossref] [PubMed]
  11. Skaro M, Nanda N, Gauthier C, et al. Prevalence of Germline Mutations Associated with Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology 2019. [Epub ahead of print]. [Crossref] [PubMed]
  12. Klein AP, Brune KA, Petersen GM, et al. Pro spective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-8. [Crossref] [PubMed]
  13. Shi C, Klein AP, Goggins M, et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009;15:7737-43. [Crossref] [PubMed]
  14. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66. [Crossref] [PubMed]
  15. Makohon-Moore AP, Matsukuma K, Zhang M, et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 2018;561:201-5. [Crossref] [PubMed]
  16. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pan- creatic intraductal papillary mucinous neo- plasm? J Am Coll Surg 2013;216:657-665; discussion 665-66. [Crossref] [PubMed]
  17. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500-7. [Crossref] [PubMed]
  18. Paini M, Crippa S, Scopelliti F, et al. Extent of surgery and implications of transection margin status after resection of IPMNs. Gastroenterol Res Pract 2014;2014:269803. [Crossref] [PubMed]
  19. Frankel TL, LaFemina J, Bamboat ZM, et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford) 2013;15:814-21. [Crossref] [PubMed]
  20. Fujii T, Kato K, Kodera Y, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery 2010;148:285-90. [Crossref] [PubMed]
  21. Miller JR, Meyer JE, Waters JA, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) 2011;13:759-66. [Crossref] [PubMed]
  22. Leng KM, Wang ZD, Zhao JB, et al. Impact of pancreatic margin status and lymph node metastases on recurrence after resection for invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Dig Surg 2012;29:213-25. [Crossref] [PubMed]
  23. Kang MJ, Jang JY, Lee KB, et al. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 2014;260:356-63. [Crossref] [PubMed]
Cite this article as: Sereni E, Luchini C, Salvia R, Pea A. Molecular and clinical patterns of local progression in the pancreatic remnant following resection of pancreatic intraductal papillary mucinous neoplasm (IPMN). Chin Clin Oncol 2019;8(2):21. doi: 10.21037/cco.2019.04.03